secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034906
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia reports Q3 2024 net loss $1.7M; CardiAMP data expected Q1 2025
------------------------------------------------------------------------

- Net loss $1.7M for Q3 2024 vs $2.6M a year ago; R&D expenses fell to $931K from $1.9M.
- CardiAMP Heart Failure Trial data lock expected Q4 2024, top line results Q1 2025.
- FDA approved protocol amendment for confirmatory Heart Failure II Trial, expanding eligibility.
- Japan's PMDA consultation scheduled for late November 2024 regarding US data-based approval.
- Closed $7.2M upsized public offering in September 2024; FDA cleared steerable introducer sheath for commercial release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774924034906/0001437749-24-034906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774924034906/bcda20241113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer